| Q44674342 | Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. |
| Q38520070 | Association of interleukin-1 alpha gene polymorphism with cerebral infarction |
| Q42726407 | Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system |
| Q40444848 | Chymotrypsin-like proteases contribute to human monocytic THP-1 cell as well as human microglial neurotoxicity |
| Q24657382 | Dementia with Lewy bodies: Definition, diagnosis, and pathogenic relationship to Alzheimer's disease |
| Q37403825 | Helicobacter hypothesis for idiopathic parkinsonism: before and beyond. |
| Q35213716 | Inflammation in central nervous system injury |
| Q64228408 | Inflammation, Infectious Triggers, and Parkinson's Disease |
| Q50658807 | Inflammation-related genes and the risk of Parkinson's disease: a multilocus approach. |
| Q80215461 | Interleukin-1 alpha polymorphism has influence on late-onset sporadic Parkinson's disease in Taiwan |
| Q47971689 | Interleukin-1 gene cluster polymorphisms and susceptibility to clinical malaria in a Gambian case-control study |
| Q38401398 | Interleukin-10-1082A/G and -592C/A polymorphisms with risk of Parkinson's disease: a meta-analysis |
| Q37100241 | Interleukin-1beta: a bridge between inflammation and excitotoxicity? |
| Q85110030 | Lack of association between IL-1β, TNF-α, and IL-10 gene polymorphisms and sporadic Parkinson’s disease in an Italian cohort |
| Q36616362 | Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease |
| Q29616300 | Neuroinflammation in Parkinson's disease: a target for neuroprotection? |
| Q36537780 | Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease |
| Q39003365 | PACAP protects against inflammatory-mediated toxicity in dopaminergic SH-SY5Y cells: implication for Parkinson's disease |
| Q24815148 | Parkinson's disease and exposure to infectious agents and pesticides and the occurrence of brain injuries: role of neuroinflammation |
| Q37878282 | Peripheral inflammation increases the damage in animal models of nigrostriatal dopaminergic neurodegeneration: possible implication in Parkinson's disease incidence. |
| Q37297356 | Polymorphic variability in the interleukin (IL)-1beta promoter conditions susceptibility to severe malarial anemia and functional changes in IL-1beta production |
| Q39720668 | Polymorphisms of interleukin-1β and MUC7 genes in burning mouth syndrome. |
| Q44640820 | Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration |
| Q26796241 | Relevance of chronic stress and the two faces of microglia in Parkinson's disease |
| Q28253697 | Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients |
| Q35510197 | Role of α-synuclein in inducing innate and adaptive immunity in Parkinson disease. |
| Q38316988 | Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. |
| Q35846770 | Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's disease |
| Q34557246 | The endotoxin-induced neuroinflammation model of Parkinson's disease. |
| Q36938295 | The role of anti-inflammatory agents in Parkinson's disease |
| Q38105903 | The role of inflammation in sporadic and familial Parkinson's disease |
| Q36692860 | Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. |